Prostate Cancer Clinical Trial
Cisplatin in Castration Resistant Prostate Cancer
It is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with CRPC by affecting AR function.
Histologic diagnosis of prostate cancer
Age 18 yrs or older
Able to provide written, informed consent
Subjects who have received docetaxel for metastatic disease are eligible if absolute neutrophil count is greater than 100 and platelet count is greater than 100,000 and their bone marrow reserve is deemed to be adequate
Subjects with castration resistant prostate cancer, as defined by having testosterone level of less than 50 Nano gram/dl, being treated with enzalutamide with a rise in PSA, confirmed with a repeat measurement within 1 to four weeks, or asymptomatic radiographic progression
Subjects with estimated glomerular filtration rate of less than 50 ml/min
Subjects with hearing impairment. The treating physician may decide which subjects should not receive cisplatin based on audiometry or based on clinical judgment.
Subjects with grade 2 or greater neuropathy
Subjects who in the opinion of the treating physician could not tolerate the standard hydration before receiving cisplatin
Chemotherapy naÃ¯ve subjects who in the opinion of the treating physician should receive docetaxel instead of enrolling on the trial and receive cisplatin
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.